Biobot Surgical Raises $15.6 Mn in Round led by ClavystBio

The company will use the new funding to expand the global use of its robotic-assisted prostate cancer treatment platform and support its entry into the U.S. market.

The company has developed Mona Lisa, a robotic platform that helps doctors perform prostate biopsies and targeted prostate cancer treatments with greater accuracy. It combines robotic technology with MRI and ultrasound images to guide the procedure.

The system is designed for transperineal prostate procedures, a method that lowers the risk of infection and helps doctors reach difficult areas of the prostate more easily.

“The objective is not simply to place systems, but to build Mona Lisa into a precision intervention platform for prostate care, connecting imaging, robotic guidance, procedure data and focal treatment workflows,” said Sim Kok Hwee, Deputy Chairman and CEO of Biobot Surgical.

“Biobot has the right combination of clinical relevance, international traction, and platform potential,” said Anselm Tan, medtech lead at ClavystBio. “The market is moving toward prostate procedures that are safer, more precise and more reproducible.”

Founded in 2007, Biobot Surgical is Singapore's first surgical robotics startup, founded through the country's strong academic and medical research ecosystem.

The company has spent years developing innovative robotic technologies to improve the diagnosis and treatment of prostate cancer and enhance patient care.

Read Also- Lytmus AI Raises $580K in Pre-Seed Round led by Boundless Ventures